Nocturnal rhythm of growth hormone in Duchenne patients: effect of different doses of mazindol and/or cyproheptadine.
Human growth hormone (hGH) inhibition may be beneficial for Duchenne muscular dystrophy (DMD) patients and slow the rate of progression of the disease. The purpose of the present investigation was 1) to assess, before any therapeutic trial, the natural growth hormone (GH) rhythm during physiological sleep in DMD patients and in normal control boys of comparable age; 2) to evaluate the effect of different doses of two potential GH inhibitors on nocturnal GH secretion in DMD patients receiving mazindol (1-4 mg), cyproheptadine (4-8 mg), or both drugs. The results from the present investigation showed 1) wide variability in nocturnal GH secretion before medication; 2) no correlation between nocturnal GH concentration and height, age, bone age, L-dopa provocative test, or Tanner staging; and 3) no consistent effect on GH release after mazindol, cyproheptadine therapy, or combined therapy.
Zatz
M
M
Departamento de Biologia, Universidade de São Paulo, Brazil.
Rapaport
D
D
Pavanello
R C
RC
Rocha
J M
JM
Vainzof
M
M
Nicolau
W
W
D000293:Adolescent; D002648:Child; D002940:Circadian Rhythm; D003533:Cyproheptadine / Q000008:administration & dosage / Q000627:therapeutic use*; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008454:Mazindol / Q000008:administration & dosage / Q000627:therapeutic use*; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000378:metabolism; D012890:Sleep / Q000502:physiology*
D007211:Indoles; D003533:Cyproheptadine; D013006:Growth Hormone; D008454:Mazindol